The Revised Federal Policy for the Protection of Human Subjects - A Summary, and an Implementation Roadmap and Matrix by Estanol, Laverne
UC Irvine
Education and Guidance Documents
Title
The Revised Federal Policy for the Protection of Human Subjects - A Summary, and an 
Implementation Roadmap and Matrix
Permalink
https://escholarship.org/uc/item/2rw6k01p
Author
Estanol, Laverne
Publication Date
2018-10-01
Supplemental Material
https://escholarship.org/uc/item/2rw6k01p#supplemental
Data Availability
The data associated with this publication are in the supplemental files.
License
CC BY-SA 4.0
eScholarship.org Powered by the California Digital Library
University of California
Page 1 of 7 
 
University of California, Irvine 
Human Research Protections 
Education & Guidance Document 
 
 
Title: The Revised Federal Policy for the Protection of Human Subjects - A Summary, and an Implementation Roadmap and 
Matrix 
Date of Last Revision:  October 2018 
Author:  Laverne Estanol, M.S., CHRC, CIP, MRQA  
Audience:  Researchers 
Citation:  https://escholarship.org/uc/item/2rw6k01p 
 
 
THE REVISED FEDERAL POLICY FOR THE PROTECTION OF HUMAN SUBJECTS 
A Summary, and an Implementation Roadmap and Matrix 
 
Background 
On January 19, 2017, the U.S. Department of Health and Human Services (HHS) and fifteen other Federal Departments and 
Agencies announced revisions to modernize, strengthen, and make more effective the Federal Policy for the Protection of Human 
Subjects that was originally promulgated as a Common Rule in 1991. The Final Rule will be effective January 21, 2019, with the 
exception of cooperative research (single IRB review) which will not be effective until January 20, 2020. The key revised elements of 
the federal policy are outlined in the table below: 
 
Additional References 
- NEJM 2017 
- Health Affairs 2017 
 
 
Table 1 
 
  
KEY REVISED 
SECTIONS 
IMPACT TO RESEARCH ADDITIONAL 
GUIDANCE 
APPLICABILITY 
 45 CFR 46.101(a) 
 
* 45 CFR 46 APPLIES TO FEDERALLY-SUPPORTED RESEARCH * 
 
 
Exempt Category Research is exempt from the 45 CFR 46 requirements   
 * DOJ, FDA, AND CPSC HAS 
YET TO ADOPT THE  
REVISED 45 CFR 46 * 
 
Preamble (page 113) 
 
SACHRP (compliance 
dates/transition provisions), May 
2017 
- Attachment A 
 45 CFR 46.101(f) When applicable, American Indian and Alaska Native Tribal Laws will be applied Preamble (page 155) 
DEFINITIONS 
 45 CFR 46.102(e) The definition of Human Subjects includes identifiable biospecimens Preamble (page 268) 
 45 CFR 46.102(l) Provides examples of what are not considered human subjects research: 
- Scholarly/Journalistic activities 
- Public Health Surveillance 
- Collection/Analysis of information/biospecimens/records for/by a criminal 
justice agency 
- Authorized operational activities by an agency for intelligence, homeland 
security, defense, or national security missions 
Preamble (page 324) 
 45 CFR 46.102(m) Defines Written (or, in writing) as paper or electronic format Preamble (page 426) 
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EXEMPT CATEGORY RESEARCH 
 45 CFR 46.104(b) 
 
 
Subpart B (Pregnant Women, Human Fetuses, and Neonates) is applicable if the 
conditions of the exemptions are met 
 
Subpart C (Prisoners) is not applicable except for research aimed at involving a 
broader subject population that only incidentally includes prisoners 
 
Subpart D (Children) is applicable to categories 1 and 4, 5, 6, 7, and 8 if the 
conditions of the exemption are met  
 
Subpart D is applicable to category 2(i and ii) when the investigator(s) do not 
participate in the activities being observed; category 2(iii) is not applicable 
Preamble (page 458) 
 
2017 AJB 
 45 CFR 46.104(d) 
 
 
Exempt categories 1-2 and 5 are further defined, and 6 remains the same 
- 1: normal educational practices not likely to adversely impact students’ 
opportunity to learn 
- 2: criteria iii specifies that an IRB can conduct a limited review for studies in 
which identifiable information is obtained/recorded 
- 5: new section for research conducted by Federal employees 
 
New categories are 3-4, and 7-8  
- 3:  research involving benign behavioral interventions with adult subjects, in 
conjunction with the collection (verbal, written, data entry, audio/visual 
recording) of information is permitted with prospective consent and at least 
one of three additional criteria are met 
- 4:  secondary research for which consent is not required is permitted if at least 
one of three additional criteria are met 
- 7:  store/maintain identifiable private information/specimens for potential 
secondary research permitted by a limited IRB review 
- 8:  research involving the use of identifiable private information/specimen for 
secondary research use for which broad consent is required, is permitted 
when 3 additional criteria are met 
Preamble (page 493) 
 
SACHRP, July 2017 
- Attachment B 
 
SACHRP (HIPAA Exemption), 
October 2017 
- Attachment B  
 
Figures 1, 2, and 3 (pages 6-7, 
below) 
 
 
 
IRB REVIEW OF RESEARCH 
 45 CFR 46.109(a) Describes Exempt Research that require limited IRB review as a condition of 
exemption 
 
*Limited IRB Review is performed at an IRB Expedited Subcommittee meeting by 
an IRB Chair or an IRB Chair-designee 
Preamble (page 749) 
 
OHRP, July 2018  
- Removes requirement of 
IRB’s review of the grant 
 
 45 CFR 46.109(f) Describes when continuing review is not required: 
- Research eligible for expedited review 
- Research reviewed by the Limited IRB review  
Process 
- Research limited to only:  data analysis, or accessing follow-up clinical data 
(performed as part of clinical care) 
Preamble (page 750) 
 
FDA, October 2018  
- Guidance 
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EXPEDITED REVIEW PROCEDURE 
 45 CFR 46.110(a) 
 
List of categories will be evaluated every 8 years Preamble (page 761) 
 
SACHRP, October 2017 
- Attachment A 
 
SACHRP, March 2018 
- Attachment A 
 
SACHRP, July 2018 
- Attachment F, not yet 
available 
 
FDA, October 2018  
- Guidance 
 46.110(b)(1) 
 
Parameters for Expedited Review includes a third criteria: 
- Research for which limited IRB review is a condition of exemption [Exempt 
categories 2(iii), 3(i), 7-8] 
Preamble (page 761) 
 
CRITERIA FOR IRB APPROVAL 
 45 CFR 
46.111(a)(3) and 
45 CFR 46.111(b) 
 
Removes pregnant women and handicapped/mentally disabled as a vulnerable 
population 
 
Specifies individuals with impaired decision-making capacity and 
economically/educationally disadvantaged as a vulnerable population 
Preamble (page 772) 
 
NIH IAL Policy, 2019 
 45 CFR 
46.111(a)(7)(i) 
 
Include adequate provisions to protect privacy of subjects / maintain confidentiality 
of data 
- HHS guidance is forthcoming 
Preamble (page 776) 
 
SACHRP, March 2018 (EU 
GDPR) 
- Attachment B 
- Addendum 
 
SACHRP, July 2018 (EU GDPR 
and Consent) 
- Attachment G, not yet 
available 
 45 CFR 
46.111(a)(8) 
 
 
 
Approval criteria for a limited IRB Review: 
- Broad consent for storage, maintenance, and secondary research use of 
identifiable information/specimens is obtained through informed consent 
[46.116(a)(1)-(4), and (a)(6), and 46.116(d)] 
- Broad consent (or waiver) is obtained [46.117) 
- If there is a change in the way identifiable private information/specimens are 
stored/maintained, there are provisions to protect the privacy of subjects and 
maintain confidentiality of data 
Preamble (page 783) 
COOPERATIVE RESEARCH 
 45 CFR 46.114(b), 
and 45 CFR 
46.114(c) 
 
Any institution engaged in cooperative research must rely upon approval by a 
single IRB for that portion of the research that is conducted in the US 
 Exceptions: 
- Cooperative research for which more than single IRB review is 
required (i.e., American Indian or Alaska Native tribal law) 
- Research for which any federal department/agency 
supporting/conducting the research determines/documents that the 
use of a single IRB is not appropriate for the particular context 
 
For research not subject to 46.114(b), an institution participating in a cooperate 
project may enter into a joint review arrangement (or rely upon the review of 
another IRB, or make similar arrangements) to avoid duplication of effort 
Preamble (page 799) 
 
NIH, 10/11/17  
- Exceptions 
- Exceptions Process 
 
UCOP, 11/13/17 
- NIH sIRB Policy 
- sIRB Reliance 
 
SACHRP, March 2018 
- Attachment D 
 
NIH, 9/12/18 
- Multi-Site Research Resource 
and Infrastructure 
Development 
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IRB RECORDS 
 45 CFR 
46.115(a)(3)   
Include a rationale for conducting continuing review of research that otherwise 
would not require continuing review [46.109(f)(1)] 
Preamble (page 814) 
 
FDA, October 2018  
- Guidance 
 45 CFR 
46.115(a)(8) 
Include a rationale for an expedited reviewer’s determination [46.110(b)(1)(i)] that 
research appearing on the expedited review list [46.110(a)] is more than minimal 
risk 
Preamble (page 814) 
 
INFORMED CONSENT 
 45 CFR 46.116(a) 
and (b) 
 45 CFR 
46.116(a)(4) 
Specifies representative as the legally authorized representative 
 
Specifies that the subject/LAR must be provided with the information that a 
reasonable person would want to have in order to make an informed decision, and 
an opportunity to discuss that information 
Preamble (page 840) 
 
California Newborn Blood Spot 
regulation 
 
2017 Hastings Center Report 
 
FDA, October 2018 
- Guidance 
 
HHS, 9/7/18   
- Informed Consent standards 
 
NAS, 7/10/18 
- Returning Individual 
Research Results 
 
NIH, 2015 
- GDS Policy 
 
NIH, 2015 
- Update to Data Management 
of Genomic Summary 
Results Under the NIH GDS 
Policy 
 
NIH, 5/30/17 
- Recommendations for 
Returning Research Results 
 
NIH, 11/1/18, Management of 
Genomic Summary Results 
Access 
- NOT-OD-19-023 
 
SACHRP, May 2017 
- Appendix F 
 
SACHRP, July 2017 
- Attachment C 
- Attachment D 
 
SACHRP, March 2018 
- Attachment A 
- Attachment C 
 
SACHRP, July 2018 
- Attachment A, not yet 
available 
 45 CFR 
46.116(a)(5) 
Begin with a concise and focused presentation of the key information, and 
organized/presented in a format that facilitates comprehension 
 
Present information in sufficient detail relating to the research, and 
organized/presented in a format that facilitates the subjects’/LARs’ understanding 
for or against participation 
 
 45 CFR 
46.116(b)(9) 
 
When this scenario is possible, include a statement that identifiers might be 
removed, and after such removal, the information/specimen could be used for 
future research studies or distributed to another investigator for future research 
studies without additional informed consent from the subject/LAR; or 
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Include a statement that the subject’s information/specimen collected as part of the 
research, even when identifiers are removed, will not be used or distributed for 
future research 
 45 CFR 
46.116(c)(7) 
Include a statement that the subject’s specimens (even when identifiers are 
removed) may be used for commercial profit and whether the subject will/will not 
share in the commercial profit 
 45 CFR 
46.116(c)(8) 
Include a statement whether clinically relevant research results, including individual 
research results, will be disclosed to subjects, and if so, under what conditions 
 45 CFR 
46.116(c)(9) 
Include a statement whether the research will (if known) or might include whole 
genome sequencing  
 45 CFR 46.116(d) Describes the 7 elements of a broad consent form 
 
 
 45 CFR 46.116(e) Describes the elements for a waiver, and the elements for an alteration, of consent 
that involves public benefit/service programs conducted by/subject to the approval 
of state/local officials 
 
IRB must determine and document that the research meets 46.116(e)(3)(i) and (ii) 
Preamble (page 936) 
 45 CFR 46.116(f) 
 
 
Describes the general waiver or alteration of consent 
 
Waiver: 
- waiver of ICF permitted if 46.116(f)(3) has been met 
- if a subject was asked to provide broad consent for 
storage/maintenance/secondary research use of identifiable private 
information/specimen [46.116(d)], and refused to consent, an IRB cannot 
waive consent for the storage/maintenance/secondary research use of the 
identifiable private information/specimen 
 
Alteration: 
- IRB may approve a consent procedure that omits some, or alters some or 
all, of the elements of the informed consent provided that the IRB satisfies 
the requirements of 46.116(f)(3) 
- IRB may not omit or alter any of the requirements in 46.116(a) 
- If a broad consent is used, an IRB may not omit or alter any of the elements 
required in 46.116(d) 
 
IRB must determine and document the research meets 46.116(f)(3) and the 
additional new elements (ii, iii, v) 
Preamble (page 959) 
 45 CFR 46.116(g) 
 
Screening, recruiting, determining eligibility is permitted when: 
- LR will obtain information through oral or written communication with the 
prospective subject/LAR, or 
- LR will obtain identifiable private information/specimen by accessing 
records/stored identifiable specimens 
Preamble (page 969) 
 45 CFR 46.116(h)   When a clinical trial has reached the status of close to recruitment, posting one 
IRB-approved clinical trial consent form is required for a clinical trial 
conducted/supported by a federal department/agency, and must be posted by the 
awardee or the federal department/agency at a publicly available federal website 
 
 If the federal department/agency supporting/conducting the clinical trial determines 
that certain information (i.e., confidential commercial information) should not be 
made publicly available on a federal website, the federal department/agency may 
permit or require redactions to the information posted 
Preamble (page 981) 
 
HHS, 8/28/18 
Post to: 
- ClinicalTrials.gov, or   
- a docket folder on 
Regulations.gov (Docket 
ID: HHS-OPHS-2018-
0021) 
 45 CFR 46.116(i) 
and 45 CFR 
46.116(j)  
The Informed Consent requirements does not preempt other applicable federal, 
state, or local laws, including American Indian or Alaska Native tribal laws that 
require additional information to be disclosed  
Preamble (page 1286) 
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Figure 1:  Data, Biospecimens, Consent, and IRB Review  
 
 
[2017 Health Affairs] 
 
  
  
45 CFR 46 does not limit the authority of a physician to provide emergency medical 
care, to the extent the physician is permitted to do so under applicable Federal, 
state, or local law (including tribal law passed by the official governing body of an 
American Indian or Alaska Native tribe) 
DOCUMENTATION OF INFORMED CONSENT 
 45 CFR 46.117(a)   Includes electronic format  
 45 CFR 
46.117(b)(2) 
Ensure that the key information [46.116(a)(5)(i)] was presented first to the subject Preamble (page 1005) 
 
FDA, October 2018  
- Guidance 
 45 CFR 
46.117(c)(1)(iii)   
A waiver of documentation of informed consent includes a new third criteria: 
- if the subject/LAR are members of a distinct cultural group/community in which 
signing forms is not the norm, an IRB may waive requirement of 
documentation of informed consent when the research presents no more than 
minimal risk of harm to subjects and provided there is an appropriate 
alternative mechanism for documenting that informed consent was obtained 
Preamble (page 1006) 
 45 CFR 
46.117(c)(2) 
When documentation of informed consent is waived, the IRB may require (subjects 
and) LARs to receive a written statement regarding the research 
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Figure 2:  Determination of Non-Exempt Human Subjects Research  
 
 
 
 
Figure 3:  Secondary Research 
   
